checkAd
    Startseite > Aktien > Bausch Health Companies > Nachrichten
    Bausch Health Companies Aktie
    5,7620
     
    EUR
    +1,21 %
    +0,0690 EUR
    Letzter Kurs 05.06.24 Tradegate
    5,6800
     
    EUR
    3.530 STK
    Geldkurs 19:32:20
    5,7190
     
    EUR
    3.500 STK
    Briefkurs 19:32:20
    ISIN: CA0717341071 · WKN: A2JQ1X · SYM: BVF · Kanada ·

    Neueste Nachrichten

    Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
    23.05.24 · Accesswire · Bausch Health Companies
    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
    17.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces 2024 Annual Meeting of Shareholder Results
    15.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
    14.05.24 · Accesswire · Bausch Health Companies
    Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
    09.05.24 · Accesswire · Bausch Health Companies
    Bausch Health Announces First Quarter 2024 Results
    02.05.24 · Accesswire · Bausch Health Companies
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 25.04.2024
    25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt
    Bausch Health to Announce First-Quarter 2024 Results on May 2
    11.04.24 · Accesswire · Bausch Health Companies
    Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
    11.04.24 · Accesswire · Bausch Health Companies
    Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
    03.04.24 · Accesswire · Bausch Health Companies
    Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
    02.04.24 · Accesswire · Bausch Health Companies
    Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
    06.03.24 · Accesswire · Bausch Health Companies